Shares of Artivion (AORT) tumbled 6.64% in after-hours trading on Monday, following the company's disappointing fourth quarter 2024 earnings report. The medical device maker missed Wall Street's expectations on both the top and bottom lines.
For the quarter, Artivion reported adjusted earnings per share of $0, falling short of analysts' consensus estimate of $0.06 per share. The company also fell short on revenue, generating $97.31 million compared to the $100.82 million projected by analysts.
The weaker-than-expected results weighed on investor sentiment, with Artivion's stock shedding over 6% of its value in extended trading hours after the earnings miss. Investors appeared disappointed by the company's lackluster performance to close out fiscal 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。